PMV Pharmaceuticals Inc (NASDAQ: PMVP) stock fell -0.40% on Monday to $2.49 against a previous-day closing price of $2.50. With 0.87 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.78 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.6099 whereas the lowest price it dropped to was $2.4312. The 52-week range on PMVP shows that it touched its highest point at $10.48 and its lowest point at $1.17 during that stretch. It currently has a 1-year price target of $9.40. Beta for the stock currently stands at 1.61.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PMVP was up-trending over the past week, with a rise of 22.66%, but this was up by 67.11% over a month. Three-month performance dropped to -66.31% while six-month performance fell -56.54%. The stock lost -75.27% in the past year, while it has lost -71.38% so far this year. A look at the trailing 12-month EPS for PMVP yields -1.56 with Next year EPS estimates of -1.75. For the next quarter, that number is -0.44. This implies an EPS growth rate of -2.66% for this year and -5.79% for next year. EPS is expected to grow by 23.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -40.91%.
Float and Shares Shorts:
At present, 45.77 million PMVP shares are outstanding with a float of 36.31 million shares on hand for trading. On Oct 30, 2023, short shares totaled 1.9 million, which was 3.93% higher than short shares on Sep 28, 2023. In addition to Dr. David H. Mack Ph.D. as the firm’s Co-Founder, CEO, President & Director, Dr. Arnold J. Levine Ph.D. serves as its Co-Founder, Director & Member of Scientific Advisory Board.
Through their ownership of 118.55% of PMVP’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 60.45% of PMVP, in contrast to 37.86% held by mutual funds. Shares owned by individuals account for 27.34%. As the largest shareholder in PMVP with 6.19% of the stake, Avoro Capital Advisor LLC holds 3,000,000 shares worth 3,000,000. A second-largest stockholder of PMVP, BlackRock Fund Advisors, holds 2,878,730 shares, controlling over 5.94% of the firm’s shares. Euclidean Capital LLC is the third largest shareholder in PMVP, holding 2,627,643 shares or 5.42% stake. With a 3.57% stake in PMVP, the JPMorgan Funds – Global Healthcar is the largest stakeholder. A total of 1,727,460 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.61% of PMVP stock, is the second-largest Mutual Fund holder. It holds 1,262,487 shares valued at 1.91 million. JPMorgan Small Cap Growth Fund holds 2.50% of the stake in PMVP, owning 1,209,783 shares worth 1.83 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PMVP since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PMVP analysts setting a high price target of $18.00 and a low target of $4.00, the average target price over the next 12 months is $9.40. Based on these targets, PMVP could surge 622.89% to reach the target high and rise by 60.64% to reach the target low. Reaching the average price target will result in a growth of 277.51% from current levels.
Summary of Insider Activity:
Insiders traded PMVP stock several times over the past three months with 0 Buys and 2 Sells. In these transactions, 0 shares were bought while 10,395 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has risen to 3 over the past year. The total number of shares bought during that period was 85,500 while 12,955 shares were sold.